Slide 1: ASX cover letter: Investors presentation as a webinar
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 26 June 2024 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (12 pages by email) For personal use only Dear Madam INVESTORS PRESENT
Slide 2: Biotron Limited Webinar
BIOTRON LIMITED 2 WEBINAR & ASX:BIT 26 June 2024 Biotron
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 Pal 444) and certain of the plans and objectives of its management. These statements are Cad ‘sta
Slide 4: Experienced team and antiviral portfolio targeting large markets
@ Experienced Board & Management team with pharma, finance and VC backgrounds Industry-leading experts focused on transformative viral treatments >e Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems and large international markets For p
Slide 5: For personal use only
For personal use only 01 • 02 • 03
Slide 6: Why HIV-1?
Why HIV-1? ~38.4m people globally living with HIV despite ARTs ~650k deaths/year from AIDS related illnesses For personal use only Biotron The increased prevalence of HIV-1 infections, % of patients on treatment due to improved disease awareness and the need for treatments to improve quality of life
Slide 7: BIT225-011 trial design
20 participants For personal use only Observation Period Treatment Period Follow-up Period
Slide 8: BIT225-011: Outcomes vs Objectives
For personal use only BIT225-011: Phase 2 Trial in Treatment-Experienced Immune Non-Responders - OUTCOMES vs OBJECTIVES PRIMARY OBJECTIVES OUTCOMES 1. Safety and tolerability Safe and generally well tolerated No deaths or drug-related SAEs AEs were similar to those seen in previous trials 2. Viral m
Slide 9: BIT225-010: Trial Overview
For personal use only BIT225-010: Phase 2 Trial in Naive, Acutely Infected HIV Population - OVERVIEW BIT225 or placebo added to cART in HIV-positive individuals commencing cART treatment (n=27, randomised 2:1) BIT225/cART or placebo/cART dosing continued for 24 weeks. At conclusion, everyone continu
Slide 10: BIT225-010: Outcomes vs Objectives
BIT225-010: Phase 2 Trial in Naive, Acutely Infected HIV Population - OUTCOMES vs OBJECTIVES PRIMARY OBJECTIVES OUTCOMES 1. Safety and tolerability Safe and generally well tolerated No deaths or drug-related SAEs D> AEs were similar to those seen in previous trials i= fo) 8 2. Impact on virus levels
Slide 11: Summary
For personal use only SUMMARY Preliminary analyses indicate that both HIV trials achieved their primary objectives BIT225 uniquely combines direct-acting antiviral and immunomodulatory activities The challenge for HIV therapies is demonstrating clinical benefit over and above current CART - Regulato
Slide 12: Biotron Limited contact details
For personal use only Biotron BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329